Summary
A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m–2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m–2, and the dose was escalated by an increase of 10 mg m–2. The maximally tolerated dose of CPT-11 was determined as 60 mg m–2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m–2 and 60 mg m–2 respectively.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aoe, K., Kiura, K., Ueoka, H., Tabata, M., Chikamori, K., Kohara, H. & Harada, M. (1997). Down-regulation of topoisomerase I induced by cisplatin. Proc Am Assoc Cancer Res 38: 15
Bonomi, P. (1996). Non-small cell lung cancer chemotherapy. In Lung Cancer – Principles and Practice, Pass HI Mitchell JB Johnson DP Turrisi AT (eds), pp. 811–835, Lippincott-Raven: Philadelphia
Fujiwara, Y., Yamakido, M., Fukuoka, M., Kudoh, S., Furuse, K., Ikegami, H. & Ariyoshi, Y. for the West Japan Lung Cancer Study Group (1994). Phase II study of irnotecan (CPT-11) and cisplatin (CDDP) in patients with small cell lung cancer (SCLC). Am Soc Clin Oncol 13: 335
Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S. & Taguchi, T. for the CPT-11 Lung Cancer Study Group (1992). A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16–20.
Gandara, D. R., Wold, E., Perez, E. A., Deisseroth, A. B., Doroshow, J., Meyers, F., McWhirter, K., Hannigan, J. & DeGregorio, M. W. (1989). Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 81: 790–794.
Gandara, D. R., Crowley, J., Livingston, R. B., Perez, E. A., Taylor, C. W., Weiss, G., Neefe, J. R., Hutchins, L. F., Roach, R. W., Grunberg, S. M., Braun, T. J., Natale, R. B. & Balcerzak, S. P. (1993). Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873–878.
Gralla, R. J., Casper, E. S., Kelsen, D. P., Braun, D. W., Dukeman, M. E., Martini, N., Young, C. W. & Golbey, R. B. (1981). Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Int Med 95: 414–420.
Hsiang, Y-H & Liu, L. F. (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722–1726.
Kaneda, N., Nagata, H., Furuta, T. & Yokokura, T. (1990). Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715–1720.
Kudoh, S., Takada, M., Masuda, N., Nakagawa, K., Itoh, K., Kususnoki, Y., Negoro, S., Matsui, K., Takifuji, N., Morino, H. & Fukuoka, M. (1993). Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung cancer xenografts. Jpn J Cancer Res 84: 203–207.
Masuda, N., Fukuoka, M., Kusunoki, Y., Matsui, K., Takifuji, S., Negoro, S., Nishioka, M., Nakagawa, K. & Takada, M. (1992a). CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225–1229.
Masuda, N., Fukuoka, M., Takada, M., Kusunoki, Y., Negoro, S., Matsui, K., Kudoh, S., Takifuji, N., Nakagawa, K. & Kishimoto, S. (1992b). CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775–1780.
Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Takifuji, N., Nakagawa, K., Tamanoi, M., Nitta, T., Hirashima, T., Negoro, S. & Takada, M. (1993). Phase I and pharmacological study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68: 777–782.
Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Nakagawa, K., Hirashima, T., Tamanoi, M., Nitta, T., Yano, T., Negoro, S., Takifuji, N. & Takada, M. (1994). Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12: 90–96.
Nakagawa, K., Fukuoka, M. & Niitani, H. The CPT-11 Lung Cancer Study Group (1993). Phase II study of irinotecan (CPT-11) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Am Soc Clin Oncol 12: 332
Ohnoshi, T., Hiraki, S., Ueoka, H., Kiura, K., Kamei, H., Horiguchi, T., Kodani, T., Maeda, T., Tabata, M., Shibayama, T., Segawa, Y., Miyatake, K., Takigawa, N. & Kimura, I. (1993). Pilot study of cyclophosphamide–doxorubicin–vincristine–cisplatin– etoposide hybrid chemotherapy in small cell lung cancer. Cancer 72: 1597–1601.
Oken, M. M., Davis, T. E., Greech, R. H., McFadden, E. T., Tormey, D. C., Carbone, P. P. & Horton, J. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655.
Rowinsky, E. K., Kaufmann, S. H., Baker, S. D., Grochow, L. B., Chen, T-L, Peereboom, D., Bowling, M. K., Sartorius, S. E., Ettinger, D. S., Forastiere, A. A. & Donehower, R. C. (1996). Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14: 3074–3084.
Tsuji, T., Kaneda, N., Kado, K., Yokokura, T., Yoshimoto, T. & Tsuru, D. (1991). CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14: 341–349.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Ueoka, H., Tabata, M., Kiura, K. et al. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. Br J Cancer 79, 984–990 (1999). https://doi.org/10.1038/sj.bjc.6690157
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690157
Keywords
This article is cited by
-
Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer
British Journal of Cancer (2003)
-
Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N2 non-small cell lung cancer
British Journal of Cancer (2002)